Jupiter Neurosciences Inc. (NASDAQ: JUNS) is expanding its brain health expertise beyond pharmaceutical development with the launch of Nugevia, a direct-to-consumer longevity product line aimed at improving mitochondrial support, mental clarity and beauty from within. The clinical-stage pharmaceutical company, known for developing JOTROL™, an enhanced orally administered resveratrol formulation, expects its consumer supplement business to account for about 60% of company sales by volume. At the center of this consumer push is cognitive health, with the key driver being Nugevia MND, a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health.
A Jupiter Neurosciences spokesperson stated that brain health is central to the company's DNA as a neuroscience company, and consumer awareness in this area is accelerating rapidly. The Nugevia MND formulation directly builds on the company's pharmaceutical expertise in neuroinflammation and CNS function, making it the most natural bridge between its clinical work and consumer wellness line. The growing demand for cognitive support is driven by aging populations worldwide seeking to maintain mental clarity, concentration and overall brain health. Jupiter Neurosciences leverages its deep history in brain diseases, including work developing drugs to treat neuroinflammation with a current focus on central nervous system disorders such as Alzheimer's and Parkinson's and rare diseases.
The global brain health supplement market is expected to reach approximately $23 billion by 2030, growing at a compound annual growth rate of around 13%. All Nugevia products are derived from JOTROL, designed to deliver therapeutically relevant, safe levels of resveratrol. The company overcame previous limitations with resveratrol by developing a delivery system that provides about nine times higher absorption and proven central nervous system penetration. JOTROL represents a first-in-class oral therapeutic that reaches effective levels in the brain and increases energy metabolism, induces mitochondrial biogenesis and reduces inflammation.
Phase one trial results determined JOTROL was safe and well-tolerated at all dose levels and demonstrated blood plasma levels 8-10-fold higher than naïve resveratrol administered in historical clinical trials. The phase two trial focuses on treating Alzheimer's, Parkinson's and a broad spectrum of CNS and rare diseases. JOTROL has patents in the U.S., Europe, China, Hong Kong and Japan protected through 2036. Jupiter Neurosciences distinguishes its supplements from single-ingredient competitors through precision-engineered intelligent stacking of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery and promote system-wide optimization.
The company has secured multiple scientists and brand ambassadors including former tennis great Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa and biohacker Jean Fallacar to demonstrate product effectiveness across different lifestyles. The company's supplement business represents the next evolution of its expertise, comprising Nugevia MND, Nugevia GLO and Nugevia PWR. A company spokesperson emphasized that Jupiter Neurosciences is first and foremost a clinical-stage biotech company that has spent the past decade developing therapies for complex central nervous system disorders, and what makes its entry into the supplement space so unique is that it is coming into it from the clinic, not the other way around.
